Description
Key facts
Detection method:Colorimetric,
Sample types:Urine, Heparin Plasma, Citrate plasma, Cell culture supernatant, Serum, EDTA Plasma,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 0.33 ng/mL,
Range:3.13 - 200 ng/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)
Product details:
Human Antithrombin III / ATIII ELISA Kit ab222507 is a rapid single-wash 90-min Sandwich ELISA to measure Human Antithrombin III / ATIII in cell culture supernatant, citrate plasma, EDTA plasma, heparin plasma, serum, urine. This SimpleStep sensitivity is 0.33 ng/mL.
How the assay works
Human Antithrombin III / ATIII SimpleStep ELISA
employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA
plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA
protocol summary in the image section for further details.
Assay Specificity
Our SimpleStep ELISA
kits use recombinant monoclonal antibodies rigorously validated to ensure the highest level of consistency and reproducibility, improved sensitivity and specificity and ease of scalability and security of supply.
Please refer to our protocol booklet for more details.
Human Antithrombin III / ATIII ELISA Kit ab222507 protocol summary
1. Mix: add samples/standards to the wells together with the capture and detector antibody cocktail. Incubate 1 hr at room temperature
2. Wash
3. Add TMB development solution - incubate for 10 min
4. Add Stop solution
5. Read the results on a plate reader at 450 nm
Design your own immunoassay
We offer the antibody pair used in this kit in a BSA and Azide-free format, ready for conjugation:
- Anti-Antithrombin III/ATIII antibody [EP5372] - BSA and Azide free (Capture)
ab244918
- Anti-Antithrombin III/ATIII antibody [EPR20132-63] - BSA and Azide free (Detector)
ab244918
Antithrombin-III (ATIII), also known as Serpin C1, is a 58 kDa extracellular glycoprotein belonging to the Serpin serine protease inhibitor superfamily. Antithrombin III functions primarily as a blood anticoagulant but also modulates inflammatory cytokine expression. Human Antithrombin-III is synthesized in the liver and is secreted as a 432 amino acid (aa) mature protein. Most circulating Antithrombin-III (90-95%) is the fully glycosylated a-isoform while the partially glycosylated Я-isoform constitutes 5-10%. The biological activity of Antithrombin-III is inherently low and is enhanced up to 1000-fold in the presence of heparin or heparin-like glycosaminoglycans. The Я-isoform of Antithrombin-III has a higher affinity for heparin. Mature human Antithrombin-III shares 90% sequence homology with mature mouse Antithrombin-III. Human Antithrombin-III inactivates thrombin and other blood coagulation factors. Human adult Antithrombin-III levels in plasma are relatively constant. However, reduction of Antithrombin-III is observed in individuals with diabetes or sepsis. Neonates also exhibit low levels of Serpin C1 in plasma.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Antithrombin III also known as ATIII or antithrombin 3 is a glycoprotein with a mass of approximately 58 kDa. This protein is mainly synthesized in the liver and circulates in the blood plasma. Antithrombin III functions as a serine protease inhibitor targeting and inhibiting several key enzymes involved in blood coagulation including thrombin and Factor Xa. Its activity is influenced by the presence of heparin which increases its inhibitory effects on these enzymes. This interaction is essential for regulating blood clot formation and maintaining hemostatic balance.
Biological function summary
Antithrombin III plays a critical role in blood clotting by specifically inhibiting clotting factors. It forms complexes with its target enzymes leading to their inactivation and preventing excessive thrombin production. The protein does not form part of larger complexes but acts independently to exert its anticoagulant function. The normal range for antithrombin 3 levels in plasma is important for ensuring a balanced blood coagulation system. Its function helps prevent inappropriate clot formation and ensures smooth blood flow through the circulatory system.
Pathways
Antithrombin III is integral to the coagulation cascade. It is primarily involved in the intrinsic and common coagulation pathways where it regulates thrombin and Factor Xa activity. This regulation prevents the unchecked formation of fibrin clots which can lead to thrombosis. ATIII works closely with proteins like heparin cofactor II and protein C which also modulate the coagulation pathway emphasizing its role in maintaining hemostatic balance. Its function is essential in controlling the coagulation cascade and ensuring that it proceeds appropriately without leading to pathology.
Antithrombin III deficiency can lead to coagulation disorders such as thrombophilia characterized by an increased risk of forming clots. Inherited or acquired deficiencies in antithrombin 3 can result in life-threatening thrombotic events. Furthermore liver diseases which affect the production of ATIII can also result in decreased antithrombin activity compounding coagulation problems. Other proteins related to this process include protein S and plasminogen which also play roles in clot regulation and fibrinolysis. Understanding the connection of antithrombin III to these pathways and diseases is important for developing effective therapeutic strategies.
